Skip to main content

Day: June 20, 2025

FLSmidth announces share buy-back programme of up to DKK 1.4 billion

COMPANY ANNOUNCEMENT NO. 11-2025 FLSmidth & Co. A/S 20 June 2025 Copenhagen, Denmark FLSmidth & Co. A/S (“FLSmidth”) today announces a share buy-back programme of up to DKK 1.4 billion to be completed before the next Annual General Meeting, which is expected to be held on 24 March 2026. This marks the company’s first share buy-back programme since 2012.ObjectiveThe company’s decision to initiate a share buy-back programme is supported by a significantly stronger and more stable financial performance (ref. Company Announcement no. 8-2025). Through strategic portfolio optimisation, our order backlog has over the past years undergone a material de-risking, with a shift toward more resilient, higher-margin technology and service offerings and reduced exposure to volatile or non-strategic projects. The decision is furthermore supported...

Continue reading

Ellomay Capital Announces the Closing of the Investment by Clal Insurance in Ellomay Capital’s 198 MW Italian Solar Portfolio

Tel-Aviv, Israel, June 20, 2025 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and the USA, today announced the closing of the investment transaction with  Clal Insurance Company Ltd. (“Clal”), a leading Israeli institutional investor, in the Company’s 198 MW solar portfolio of operating projects and projects under construction and development in Italy. In consideration for its investment in the Italian solar portfolio, Clal received a 49% interest in the portfolio. For more information concerning the transaction and agreements with Clal, including the warrant to purchase ordinary shares of the Company issued to Clal upon consummation of the transaction, see Item 4 of...

Continue reading

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST           CHMP recommends third indication for darolutamide for patients with advanced prostate cancerCHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union.Positive opinion is based on results from the pivotal Phase III ARANOTE trial.Pending approval, this broadened indication would give doctors the option to use darolutamide plus ADT, with or without chemotherapy (docetaxel), offering greater flexibility to tailor treatment plans to meet mHSPC patients’ needs.Orion’s collaboration partner Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Continue reading

FLSmidth signs agreement to divest its Cement business to become a pure-play supplier of technology and services to the mining industry

COMPANY ANNOUNCEMENT NO. 10-2025 FLSmidth & Co. A/S20 June 2025 Copenhagen, Denmark Today, FLSmidth announces that it has entered into an agreement to divest its Cement business to an affiliate of Pacific Avenue Capital Partners, a global private equity firm focused on carve-outs and other complex transactions, for a total initial consideration of EUR 75 million, corresponding to approximately DKK 550 million (Enterprise Value), plus a conditional deferred cash consideration of up to EUR 75 million, corresponding to approximately DKK 550 million. In early 2023, FLSmidth embarked on a strategic journey with the announcement of new pure-play strategies for its Mining and Cement businesses (ref. Company Announcement no. 2-2023). Since then, FLSmidth has simplified and rightsized both businesses to further strengthen their respective...

Continue reading

Everything Blockchain Plans $10M Strategic Acquisition of SOL, XRP, SUI, TAO & HYPE — Front Running Wall Street

Jacksonville, Florida, June 20, 2025 (GLOBE NEWSWIRE) — Everything Blockchain Inc. (OTC: EBZT) announced today its strategic plan to deploy $10 million into five of the fastest growing blockchain networks—Solana (SOL), XRP, Sui (SUI), Bittensor (TAO), and Hyperliquid (HYPE), positioning ahead of the anticipated institutional crypto wave. This strategy positions EBZT as the first U.S. public equity to implement a multi-token staking treasury focused on blockchain networks seeking institutional adoption. With its small float, EBZT offers retail investors scarce exposure to top crypto assets before Wall Street institutions enter at scale. Notably, similar public crypto treasury plays such as SolStrategies and Janover have recently raised hundreds of millions of dollars, demonstrating strong investor appetite for crypto treasury strategies,...

Continue reading

KBR Announcement on HomeSafe Alliance Global Household Goods Contract

HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) — HomeSafe Alliance, a KBR (NYSE: KBR) Joint Venture, informed us on June 18, 2025, that U.S. Transportation Command (TRANSCOM) has terminated HomeSafe’s role in the Global Household Goods Contract, a contract designed to improve the moving system for military service members and their families. We have been and will continue to work with HomeSafe to complete its obligations to TRANSCOM and the military service members and families that it serves. This development is not expected to have a material effect on the outlook for KBR’s adjusted EBITDA for 2025 as the program was not assumed to contribute to profits in this initial year of move activity. For additional information please read the HomeSafe Alliance press release linked below: HomeSafe Alliance Announces TRANSCOM’s Notice to...

Continue reading

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Recommendation based on CABINET Phase III trial results, which demonstrated statistically significant and clinically meaningful reductions in risk of disease progression or death with Cabometyx versus placebo3,4 European Commission decision expected Q3 2025PARIS, FRANCE, 20 June 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET)...

Continue reading

Danish Ministry of Digitalization begins testing F2 with open source document editing

Press Release no. 04/2025 Danish Ministry of Digitalization begins testing F2 with open source document editingCopenhagen, June 20, 2025The Danish Ministry of Digitalization has announced the launch of a pilot project to explore digital sovereignty, using cBrain’s (NASDAQ: CBRAIN) F2 platform as the foundation for testing an integrated open source alternative to traditional office software. Digitalization Minister Caroline Stage stated: “We have a political obligation to ensure that our IT systems are not dependent on a few large companies. This pilot is a welcome and concrete first step in that direction.” A group of employees within the ministry’s department will begin using F2 with a newly integrated document editing module based on Collabora, the open source solution built on LibreOffice. The pilot will assess whether Collabora,...

Continue reading

Resolutions of the Annual General Meeting of Shareholders from 20 June 2025

The annual general meeting of shareholders of AS Trigon Property Development (registry code: 10106774; hereinafter the “Company”) was held on 20 June 2025 in Tallinn, Pärnu mnt 18. The annual general meeting started at 10:00. 2,570,164 votes represented by the shares of the Company, i.e. 57,127% of all the votes represented by the shares of the Company, participated at the meeting. Therefore, the annual general meeting was competent to pass resolutions regarding the items on the agenda. Resolutions of the annual general meeting:           1.     Approval of the annual report of the Company for the financial year 2024 To approve the annual report of the Company for the financial year 2024, in accordance with which the balance sheet value of the Company as at 31 December 2024 was 1,873,680 euros and the net profit for the financial year...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.